Literature DB >> 16460689

Some implications of receptor theory for in vivo assessment of agonists, antagonists and inverse agonists.

S Stevens Negus1.   

Abstract

Drug effects can be classified into three major phenotypes: agonist, antagonist and inverse agonist. Agonist and inverse agonist effects are associated with receptor activation and inactivation, respectively, whereas antagonism implies that a drug produces no effect when administered alone but blocks the effects of agonists and inverse agonists. Attention has only recently begun to focus on the theoretical and clinical implications of inverse agonists, and studies of inverse agonism have also stimulated revisions in receptor theory. This commentary addresses two specific issues related to the application of receptor theory to studies of inverse agonists in vivo. First, principles of receptor theory suggest that increasing drug doses produce a graded pharmacological stimulus that is transduced by receptor-containing tissue into a biological response. However, assays vary in their ability to detect those responses, and any given assay provides only a narrow window on the full range of underlying drug effects. Consequently, in vivo assessment of inverse agonists will benefit from development of assays sensitive to graded inverse agonist effects. Second, detection of inverse agonist effects requires some preexisting level of receptor activity (or tone). This tone can result from at least two sources: (a) endogenous ligands for the receptor, or (b) constitutive receptor activity. Strategies for discriminating these two sources of tone will also contribute to the in vivo assessment of inverse agonist effects. Studies with intermediate efficacy ligands may be especially helpful in this regard, because their effects are differentially influenced by endogenous agonist tone versus constitutive receptor tone.

Mesh:

Substances:

Year:  2006        PMID: 16460689      PMCID: PMC1866283          DOI: 10.1016/j.bcp.2005.12.038

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  21 in total

Review 1.  Inverse, protean, and ligand-selective agonism: matters of receptor conformation.

Authors:  T Kenakin
Journal:  FASEB J       Date:  2001-03       Impact factor: 5.191

Review 2.  Multiple signaling states of G-protein-coupled receptors.

Authors:  Dianne M Perez; Sadashiva S Karnik
Journal:  Pharmacol Rev       Date:  2005-06       Impact factor: 25.468

3.  In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.

Authors:  Kirsten M Raehal; John J Lowery; Castigliano M Bhamidipati; Ryan M Paolino; Jennifer R Blair; Danxin Wang; Wolfgang Sadée; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2005-02-16       Impact factor: 4.030

4.  Constitutively active micro opioid receptors mediate the enhanced conditioned aversive effect of naloxone in morphine-dependent mice.

Authors:  James R Shoblock; Nigel T Maidment
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

Review 5.  Stress-induced behavioral responses and multiple opioid systems in the brain.

Authors:  K Yamada; T Nabeshima
Journal:  Behav Brain Res       Date:  1995-03       Impact factor: 3.332

Review 6.  Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

Authors:  Wolfgang Sadée; Danxin Wang; Edward J Bilsky
Journal:  Life Sci       Date:  2004-12-08       Impact factor: 5.037

7.  Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.

Authors:  Ellen A Walker; Steven N Sterious
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

8.  An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity.

Authors:  D Morgan; C D Cook; M A Smith; M J Picker
Journal:  Anesth Analg       Date:  1999-02       Impact factor: 5.108

9.  Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain.

Authors:  L J Sim; D E Selley; S I Dworkin; S R Childers
Journal:  J Neurosci       Date:  1996-04-15       Impact factor: 6.167

Review 10.  Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands.

Authors:  J Bergman; C P France; S G Holtzman; J L Katz; W Koek; D N Stephens
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

View more
  5 in total

1.  N⁶-(benzyloxymethyl)adenosine is a novel anticytokinin, an antagonist of cytokinin receptor CRE1/AHK4 of Arabidopsis.

Authors:  D M Krivosheev; S V Kolyachkina; S N Mikhailov; V I Tararov; B F Vanyushin; G A Romanov
Journal:  Dokl Biochem Biophys       Date:  2012-07-08       Impact factor: 0.788

2.  Classification of 5-HT(1A) receptor ligands on the basis of their binding affinities by using PSO-Adaboost-SVM.

Authors:  Zhengjun Cheng; Yuntao Zhang; Changhong Zhou; Wenjun Zhang; Shibo Gao
Journal:  Int J Mol Sci       Date:  2009-07-29       Impact factor: 6.208

3.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats.

Authors:  Jun-Xu Li; Alison Unzeitig; Martin A Javors; Kenner C Rice; Wouter Koek; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2009-08-17       Impact factor: 4.030

4.  Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids.

Authors:  D E Selley; M L Banks; C M Diester; A M Jali; L P Legakis; E J Santos; S S Negus
Journal:  J Pharmacol Exp Ther       Date:  2020-12-22       Impact factor: 4.030

5.  Comparison of Cannabinoid CB(1) Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [F]MK-9470.

Authors:  Mathieu Verdurand; Vu Nguyen; Daniela Stark; David Zahra; Marie-Claude Gregoire; Ivan Greguric; Katerina Zavitsanou
Journal:  Int J Mol Imaging       Date:  2011-12-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.